We are the Peptide Experts

JPT Peptide Technologies is the leading manufacturer of custom peptides and innovative peptide-based products for research and clinical applications. For more than 15 years we have been serving the worldwide biomedical community with science and quality driven products and services.

Located in our state-of-the-art laboratories in Berlin, Germany, JPT operates according to the most recent ISO 9001:2015 regulations.

Custom Peptide Synthesis

Product Finder

Search by keyword

Search by scientific field

Research Fields

Cell Therapy & Vaccines

JPT offers a large portfolio of peptide products and services supporting all development phases of new cell therapies and vaccines. These products range from discovery tools for epitope and target identification, to various peptide formats for immune monitoring and clinical grade peptides to support clinical vaccination and cell therapy trials. Learn more

Immunology

JPT has developed a variety of unique peptide-based products allowing systematic evaluation of cellular and humoral immunity. In addition to peptide formats allowing T-cell and B-cell epitope discovery, antigen-specific T-cell stimulation and immune monitoring our clinical grade products support clinical trials for the development of new immunotherapeutics and vaccines. Learn more

Neo-Epitope Discovery & Therapy

Neo-epitopes are important targets for individualized cancer immunotherapy. JPT’s high-throughput peptide techniques enable access to customized peptide products for neo-epitope prioritization and validation, individualized therapy development and immune monitoring. Learn more

Proteomics

Proteomics is the study of a cell's protein inventory at different times by protein identification and quantification. The application of mass spectrometry and more specifically LC-MS/MS has tremendously facilitated this process. JPT developed proprietary approaches for the provision of quantified custom peptides and ready-to-use products enabling protein biomarker identification and quantitation. Learn more

COVID-19

JPT was the first company responding to the Covid-19 pandemic with the launch of a broad SARS CoV-2 genome spanning portfolio of peptide tools. The ready to use and custom peptide tools include antigen spanning PepMixTM peptide pools and PepStarTM peptide microarrays of SARS-CoV-2 wild type and mutated antigen sequences as well as antigens from other relevant corona viruses. Learn more

News

NEW: Delta & Kappa SARS-CoV-2 PepMixes™

Here, we announce the launch of PepMix™ peptide pools for Spike protein and the corresponding RBD domain of the following SARS-CoV-2 variants of concern (VOC):

• NEW: Kappa, B.1.617.1

• NEW: Delta, B.1.617.2

• Alpha, B.1.1.7

• Beta, B.1.351

• Gamma, P.1

• Epsilon, B.1.429

July 2021

Identify Epitope Resolved Antibody Responses with SARS-CoV-2 Peptide Microarrays

In a recent publication using JPT’s RepliTope™ Antigen Collection Pan-Coronavirus peptide microarrays which display the whole SARS-CoV-2 proteome as well as relevant common cold corona virus antigens, a widespread cross-reactivity was detected across immunodominant antigen regions. Importantly, a statistically significant discrimination between COVID-19 patients and controls could be achieved allowing selection of dedicated peptides for further development.

March 2021

NEW: Virus-spanning PepMix™ Select Epitope Pools from JPT

We are happy to expand our PepMix™ Pool portfolio with a new line of PepMix™ Select Pools:

Virus-specific epitope pools for CMV, EBV, BKV, HHV6 and HAdV5
Multiple antigens covering the whole virus in one pool
Defined HLA class I & II-restricted immunodominant T-cell epitopes
Elicit virus-specific strong immune responses

February 2021

Navigation